Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients

Liver International

Volumn 34, Issue 4, 2014, Pages 551-557

  Frei, Pascal ^a   Leucht, Anna Kathrin ^a   Held, Ulrike ^b   Kofmehl, Reto ^b   Manser, Christine N ^a   Schmitt, Johannes ^a   Mertens, Joachim ^a   Rau, Monika ^a   Baur, Katharina ^a   Gerlach, Tilman ^c   Negro, Francesco ^d   Heim, Markus ^e   Moradpour, Darius ^f   Cerny, Andreas ^g   Dufour, Jean François ^h   Müllhaupt, Beat ^a   Geier, Andreas ^a,i  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Department of Gastroenterology and Hepatology Kantonsspital St Gallen ^*  (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g Clinica Luganese Moncucco   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Age; Elderly; Hepatitis C therapy; Host factor; Matched pair analysis; Pegylated interferon alfa; Ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AGE; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIVERTICULITIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENDER; GENOTYPE; GERIATRIC DISORDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; STATISTICAL ANALYSIS; SUBARACHNOID HEMORRHAGE; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS CLASSIFICATION; VIRUS LOAD;

AGE; ELDERLY; HEPATITIS C THERAPY; HOST FACTOR; MATCHED PAIR ANALYSIS; PEGYLATED INTERFERON-ALFA; RIBAVIRIN;

AGE FACTORS; AGED; GENOTYPE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MATCHED-PAIR ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RIBAVIRIN; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84895820986     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12279     Document Type: Article

References (30)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.
2. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31(Suppl. 2): 30-60.
3. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
8. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
9. Poordad F, McCone J Jr, Bacon BR. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
10. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
11. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
12. Thabut D, le Calvez S, Thibault V, et al. Hepatitis C in 6, 865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006; 101: 1260-7.
13. Watson JP, Brind AM, Chapman CE, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996; 38: 269-76.
14. Miyake Y, Iwasaki Y, Yamamoto K. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer 2010; 127: 989-96.
15. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23.
16. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
17. Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010; 30: 527-37.
18. Oze T, Hiramatsu N, Yakushijin T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 2011; 54: 604-11.
19. Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008; 28: 9-16.
20. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383-91.
21. Gramenzi A, Conti F, Camma C, et al. Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis 2012; 44: 674-80.
22. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995; 10: 246-9.
23. R Development Core Team. R: A language and environment for statistical computing, In. Vienna, Austria: R Foundation for Statistical Computing, 2012.
24. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21, 21 e1-6.
25. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
26. Organization WH. Chapter 1: Global Health: Today's Challenges. The world health report, 2003.
27. Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 2006; 54: 549-50.
28. Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat 2012; 19: 677-84.
29. Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-43.
30. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.